LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hi fellow warriors! This week too, despite my commitments, I found something interesting for you. Science is moving fast! Stay strong and fight on!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.
​For more details on everything I talk about here, you can always visit ProstateWarriors.com.​

Clinical Research

• Phase 1 Trial: Radioligand Therapy with AB001​
  The FDA has approved a Phase 1 clinical trial in the USA for AB001, a new radioligand therapy designed to treat metastatic castration-resistant prostate cancer (mCRPC). AB001 targets prostate-specific membrane antigen (PSMA) using the alpha emitter lead-212, which delivers high-energy radiation over a short range, aiming to concentrate its effect in cancer cells while limiting harm to surrounding tissue. Preclinical research and an exploratory Phase 0 study in Norway demonstrated that microdoses of AB001 localized to metastatic lesions and were safely administered, clearing predictably without immediate adverse effects. The upcoming U.S. trial will escalate doses to therapeutic levels to assess the therapy’s safety, tolerability, and initial anti-tumor activity in men with mCRPC. Alpha emitters like lead-212 are being investigated for their potentially greater potency compared to existing lutetium-177-based radioligand therapies, despite challenges in their supply and handling.
  ​
• Phase 2 Trial: Repurposing Memantine for Advanced Prostate Cancer​
  Chinese researchers have launched a Phase 2 clinical trial to explore memantine, an Alzheimer’s drug, as a potential treatment for advanced metastatic castration-resistant prostate cancer (mCRPC), particularly in cases with neuroendocrine differentiation. This is an example of drug repurposing, utilizing an established medication for a new application. Memantine, known for blocking NMDA receptors in the brain, has been found to also disrupt these receptors in tumors, which play a role in fueling cancer growth and spread. Preclinical studies show memantine can directly inhibit tumor cell proliferation and invasion, enhance the immune system’s anti-cancer capabilities, and trigger prostate cancer cell death at concentrations significantly lower than other repurposed drugs like metformin. The trial will test memantine in combination with standard treatments, with a remarkably small financial investment due to the drug’s known safety and affordability.
  ​
• Phase 1b Trial Results: Investigational Immunotherapy OST-504​
  A Phase 1b study evaluating OST-504, an investigational immunotherapy for biochemically recurrent prostate cancer, has completed its last patient visit, with results anticipated later in 2025.OST-504 is a live attenuated Listeria monocytogenes-based construct that delivers 24 prostate cancer-associated antigens. This platform is designed to elicit antigen-specific T cell responses and to modulate the tumor microenvironment by reducing immune-suppressing cells, thereby training the immune system to specifically identify and attack prostate cancer cells. The open-label trial enrolled seven men whose disease recurred after radical prostatectomy or radiation therapyand who were not on androgen deprivation therapy.
  ​
• Phase 2 Trial: Pasritamig Bispecific Antibody​
  Pasritamig, a bispecific antibody, is being developed for late-line metastatic castration-resistant prostate cancer, with a Phase 3 trial now underway. This antibody works by engaging both T cells (via CD3) and prostate cancer cells (via the kallikrein-related peptidase 2 (KLK2) protein, specific to prostate tissue), redirecting T cells to targeted cancer cells to initiate immune-mediated killing while minimizing off-tumor toxicity. A first-in-human trial in heavily pre-treated mCRPC patients showed promising clinical activity, with nearly half achieving a reduction of prostate-specific antigen (PSA) by at least 50% and some durable radiographic responses. The median radiographic progression-free survival in that trial was close to eight months. The ongoing randomized, double-blind, placebo-controlled KLK2-comPAS trial aims to evaluate whether pasritamig can extend overall survival.

​
Preclinical Research & Reviews

• Dietary Patterns in Prostate Cancer Prevention and Management​
  A comprehensive new review published in European Urology analyzed 49 cohort studies and 14 randomized controlled trials to assess the impact of dietary patterns on prostate cancer risk, progression, and mortality. The review concluded that diets rich in plant-based foods, fruits, vegetables, whole grains, healthy proteins, and “good” fats, while limiting processed or sugary foods and red meat, were associated with lower risks of aggressive prostate cancer and cancer-related death. Such eating patterns also appeared to slow disease progression after a prostate cancer diagnosis. Conversely, Western dietary patterns, heavy on processed meats, refined grains, and added sugars, were linked to higher odds of aggressive disease and death. The evidence for diet’s role in slowing progression and reducing cancer-specific mortality after diagnosis was found to be stronger than its role in preventing prostate cancer outright, though positive signals were observed for both. While the Mediterranean diet showed little consistent evidence for preventing prostate cancer onset, it was associated with reducing disease progression and improving survival after diagnosis.
  ​
  ​

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If you this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max